Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 2/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 3/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.31 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20082396 | 0.89 | PDCD1 (0.42) | PDCD1CD274TLR9TLR8TLR7 | |
| Hydrochloric Acid SCHEMBL15006961 | 0.87 | PDCD1 (0.41) | PDCD1CD274TLR9TLR8TLR7 | |
| SCHEMBL7904788 | 0.83 | PDCD1 (0.37) | PDCD1CD274TLR9TLR8TLR7 | |
| SCHEMBL15933517 | 0.77 | PDCD1 (0.43) | PDCD1CD274TLR9TLR8TLR7 | |
| SCHEMBL20330389 | 0.77 | PDCD1 (0.43) | PDCD1CD274TLR9TLR8TLR7 | |
| SCHEMBL21126220 | 0.77 | PDCD1 (0.44) | PDCD1CD274TLR9TLR8TLR7 | |
| SCHEMBL3720213 | 0.77 | PDCD1 (0.44) | PDCD1CD274TLR9TLR8TLR7 | |
| SCHEMBL112848 | 0.77 | PDCD1 (0.44) | PDCD1CD274TLR9TLR8TLR7 | |
| SCHEMBL12092418 | 0.77 | PDCD1 (0.44) | PDCD1CD274TLR9TLR8TLR7 | |
| SCHEMBL13531866 | 0.75 | HDAC2 (0.46) | PDCD1CD274TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215016-A1 | ISOXAZOLE-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE | Shanghai SIMR Biotechnology Co., Ltd (CN) | 2025-07-03 | — | — | US | disclosed |
| EP-4506348-A1 | ISOXAZOLE-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE | Shanghai Simrd Biotechnology Co., Ltd (CN) | 2025-02-12 | — | — | EP | disclosed |
| US-20240018120-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2024-01-18 | — | — | US | disclosed |
| CN-116854680-A | Isoxazole-heterocycle derivatives, pharmaceutical composition and application | 上海赛默罗生物科技有限公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023185704-A1 | ISOXAZOLE-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE | 上海赛默罗生物科技有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023159307-A1 | POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | REPARE THERAPEUTICS INC. (CA) | 2023-08-31 | — | — | WO | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4223369-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | Incyte Corporation (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| EP-2247590-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2010125101-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010125101-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010098495-A1 | IMIDAZOLYLPYRAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010098487-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| US-20100063023-A1 | Bicyclic and Tricyclic Substituted 6-Methylidene Carbapenems as Broad Spectrum Beta-Lactamase Inhibitors | WYETH (US) | 2010-03-11 | — | — | US | disclosed |
| EP-2090576-A1 | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators | Merz Pharma GmbH & Co.KGaA (DE) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009095253-A1 | 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009095254-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| EP-2085398-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018120-A1 | MAGL INHIBITORS | MAG, MAGI3, MAGT1 | PDCD1 1951/4885CD274 2159/4885TLR9 4679/4885 |
| US-20100063023-A1 | Bicyclic and Tricyclic Substituted 6-Methylidene Carbapenems as Broad Spectrum Beta-Lactamase Inhibitors | MGAM, CYP2C18, BCAT2 | PDCD1 1977/4885CD274 2236/4885TLR9 1224/4885 |
| US-20250215016-A1 | ISOXAZOLE-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE | GABRA5, GABRA1, CYP3A5 | PDCD1 3077/4885CD274 3001/4885TLR9 3485/4885 |
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | PDCD1 2331/4885CD274 2512/4885TLR9 3269/4885 |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | PDCD1 3348/4885CD274 3380/4885TLR9 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.